SARS‐CoV‐2–host proteome interactions for antiviral drug discovery

SARS‐CoV‐2–host proteome interactions for antiviral drug discovery

Abstract Treatment options for COVID‐19, caused by SARS‐CoV‐2, remain limited. Understanding viral pathogenesis at the molecular level is critical to develop effective therapy. Some recent studies have explored SARS‐CoV‐2–host interactomes and provided great resources for understanding viral replica...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Xiaonan Liu, Sini Huuskonen, Tuomo Laitinen, Taras Redchuk, Mariia Bogacheva, Kari Salokas, Ina Pöhner, Tiina Öhman, Arun Kumar Tonduru, Antti Hassinen, Lisa Gawriyski, Salla Keskitalo, Maria K Vartiainen, Vilja Pietiäinen, Antti Poso, Markku Varjosalo
Format: article
Langue:EN
Publié: Wiley 2021
Sujets:
drug discovery
mass spectrometry
proteomics
SARS‐CoV‐2
virus–host interactions
Biology (General)
QH301-705.5
Medicine (General)
R5-920
Accès en ligne:https://doaj.org/article/c87ddbd7671244cc9c1ca8b5b5555d62
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/c87ddbd7671244cc9c1ca8b5b5555d62

Documents similaires